Citius Pharmaceuticals is an American specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Citius Pharmaceuticals news
25.05.2022
Citius Pharmaceuticals will spin off its I/ONTAK drug development and commercialization division, which has completed three phases of trials, into a separate public company. The company's other assets, including Mino-Lok, will remain in Citius. The deal is expected to close in the second half of 2022.
Source: 
citiuspharma.com
citiuspharma.com
13.05.2022
Citius Pharmaceuticals' GAAP loss for 6 months of fiscal year 2022 was $16.786 million, up 36.8% from $12.269 million in the previous year.
Source: citiuspharma.com
citiuspharma.com
11.02.2022
Citius Pharmaceuticals reported a GAAP loss of $9.225 million for the first 3 months of fiscal year 2022, up 13.5% from $8.147 million in the prior year.
Source: citiuspharma.com
citiuspharma.com
16.12.2021
Citius Pharmaceuticals' GAAP loss for fiscal year 2021 was $23.054 million, up 31.4 percent from $17.548 million in the previous year.
Source: citiuspharma.com
citiuspharma.com
General information
| Company name | Citius Pharmaceuticals |
|---|---|
| Tags | #pharmacy, #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 11 Commerce Drive First Floor Cranford, NJ 07016 United States |
| Mailing address | 11 Commerce Drive First Floor Cranford, NJ 07016 United States |
| Website | ir.citiuspharma.com |
| Information disclosure | www.sec.gov |
English (US) 